```html

Uraemia‑Associated Pericarditis

Overview

Uraemia‑associated pericarditis (also called uremic pericarditis) is inflammation of the pericardial sac that occurs in the setting of advanced kidney failure (usually when the estimated glomerular filtration rate < 15 mL/min/1.73 m² or when a patient is on dialysis). The condition is a manifestation of the systemic effects of accumulated uremic toxins.

• Who it affects: Most commonly adults with end‑stage renal disease (ESRD). It can also occur in children with severe chronic kidney disease (CKD) but is rare.
• Prevalence: Historically, uremic pericarditis was reported in up to 20 % of patients with untreated uremia. With modern dialysis protocols, the incidence has dropped to < 5 % in patients receiving regular hemodialysis, but it remains a leading cause of pericardial disease in the ESRD population [1][2].

Symptoms

The presentation can be subtle or dramatic. Below is a complete list of typical manifestations, with brief explanations:

• Chest pain – Classically sharp, pleuritic, and worsens when lying flat; may improve when sitting up and leaning forward.
• Fever – Low‑grade temperature (often < 38 °C) due to inflammation.
• Shortness of breath (dyspnea) – From reduced cardiac filling or associated fluid overload.
• Palpitations – Irregular heartbeats may be sensed when pericardial irritation affects conduction.
• Fatigue & weakness – Common in renal failure and amplified by cardiac compromise.
• Peripheral edema – Swelling of legs/ankles due to fluid retention.
• Pericardial friction rub – A high‑pitched, scratchy sound heard on auscultation; pathognomonic when present.
• Hypotension – May develop if a large pericardial effusion restricts cardiac output (tamponade physiology).
• Syncope or presyncope – Result of sudden drops in blood pressure, especially with tamponade.
• Night sweats & malaise – Nonspecific but frequently reported by dialysis patients.

Causes and Risk Factors

Underlying Mechanism

Uraemia‑associated pericarditis results from the accumulation of nitrogenous waste products (urea, creatinine, guanidino compounds) and inflammatory cytokines that irritate the pericardium. The exact toxin(s) remain unclear, but factors include:

• Elevated serum urea (> 100 mg/dL) and creatinine.
• Metabolic acidosis, hyperphosphatemia, and secondary hyperparathyroidism.
• Volume overload and uremic pericardial fluid rich in protein and inflammatory cells.

Risk Factors

• Advanced CKD/ESRD – Especially when not yet on dialysis or inadequately dialyzed.
• Inadequate dialysis – Missed sessions, low‑efficiency ultrafiltration, or use of low‑flux dialyzers.
• Rapid rise in BUN/creatinine – Acute worsening of renal function.
• Volume overload – Positive fluid balance > 2 L over 24 h.
• Hypoalbuminemia – Low serum albumin (< 3 g/dL) predisposes to pericardial effusion.
• Concurrent infections – Bacterial or viral infections heighten systemic inflammation.
• Autoimmune disorders – Lupus or vasculitis can compound pericardial inflammation.

Diagnosis

Diagnosis integrates clinical suspicion with targeted investigations. The goals are to confirm pericardial inflammation, assess for effusion, and exclude other causes (e.g., infectious, neoplastic, ischemic).

Clinical Assessment

• History focused on CKD stage, dialysis schedule, recent missed sessions, and symptom chronology.
• Physical exam for friction rub, jugular venous distension, pulsus paradoxus, and signs of fluid overload.

Laboratory Tests

• Renal panel: BUN, creatinine, electrolytes, eGFR.
• Inflammatory markers: ESR, CRP – often modestly elevated.
• Cardiac biomarkers: Troponin may be mildly raised due to inflammation but not to the level seen in MI.
• Pericardial fluid analysis (if tapped): Usually exudative with high protein, low glucose, and sterile cultures.

Imaging

• Echocardiography: First‑line; identifies pericardial effusion, assesses size (> 10 mm is significant), and looks for signs of tamponade (right‑ventricular diastolic collapse, exaggerated respiratory variation in mitral inflow). It also evaluates left‑ventricular function.
• Chest X‑ray: May show an enlarged, “water‑bottle” cardiac silhouette if effusion is large.
• CT or MRI: Reserved for equivocal cases; can differentiate pericardial thickening from effusion and evaluate for constrictive physiology.

Diagnostic Criteria (simplified)

Uraemia‑associated pericarditis is diagnosed when all three are present:

1. Advanced renal failure (eGFR < 15 mL/min/1.73 m² or dialysis‑dependent).
2. Clinical features of pericarditis (chest pain, friction rub, ECG changes, or pericardial effusion).
3. Absence of another identifiable cause (negative bacterial cultures, no recent MI, no autoimmune flare).

Treatment Options

Treatment aims to eliminate the uremic insult, control inflammation, and manage the effusion.

Dialysis Optimization

• Intensify dialysis: Daily or every‑other‑day hemodialysis, or continuous renal replacement therapy (CRRT) in critically ill patients, rapidly reduces toxin load.
• Use high‑flux or high‑efficiency dialyzers to improve middle‑molecule clearance.
• Ultrafiltration: Careful removal of excess fluid (target < 1.5 L/day) to relieve pressure on the pericardium.

Pharmacologic Therapy

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Generally avoided in ESRD because of nephrotoxicity and platelet effects; if used, choose short courses of low‑dose ibuprofen with close monitoring.
• Corticosteroids: Prednisone 0.5 mg/kg daily can be considered when pericarditis persists despite dialysis optimization, or when an inflammatory component is prominent. Taper over 2–4 weeks to minimize side effects.
• Colchicine: 0.6 mg once daily (adjusted for renal function) reduces recurrence risk in other forms of pericarditis; limited data in uremic pericarditis but may be useful in selected patients.

Procedural Interventions

• Pericardiocentesis: Indicated for large effusions (> 20 mm) or tamponade physiology. Performed under echocardiographic guidance; fluid is sent for analysis.
• Surgical pericardial window: Considered when recurrent effusions occur despite optimal dialysis.

Supportive Measures

• Analgesia with acetaminophen (≤ 3 g/day) for pain control.
• Fluid‑restriction counseling (usually 1–1.5 L/day) to avoid volume overload.
• Electrolyte management—especially potassium and phosphate—to prevent arrhythmias.

Living with Uraemia‑Associated Pericarditis

Daily Management Tips

• Adhere to dialysis schedule: Missing or shortening sessions dramatically raises risk.
• Monitor weight daily: Aim for a “dry weight” target; sudden gains > 2 kg may herald fluid overload.
• Track symptoms: Keep a log of chest discomfort, shortness of breath, or new swelling and share with your nephrologist.
• Medication reconciliation: Avoid over‑the‑counter NSAIDs, herbal supplements with unknown renal impact, and confirm dosages of prescribed drugs.
• Dietary measures: Low‑sodium (< 2 g/day) and moderate protein intake (0.8 g/kg) to limit uremic toxin production.
• Vaccinations: Stay up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines to reduce infection‑triggered inflammation.
• Physical activity: Gentle aerobic exercise (e.g., walking 20–30 min most days) improves cardiovascular reserve without overtaxing the heart.
• Stress management: Mind‑body techniques (deep breathing, meditation) can lower blood pressure and sympathetic drive.

Prevention

• Early referral to nephrology: Timely preparation for renal replacement therapy reduces the period of severe uremia.
• Optimal dialysis prescription: Tailor session length and frequency to achieve BUN < 60 mg/dL and maintain target Kt/V ≥ 1.2.
• Fluid and salt control: Educate patients on reading food labels and limiting processed foods.
• Regular cardiac screening: Annual echocardiograms for dialysis patients help detect subclinical effusions.
• Prompt treatment of infections: Early antibiotics for bacteremia or pneumonia diminish systemic inflammation.
• Address hyperparathyroidism: Vitamin D analogs or calcimimetics can reduce calcium‑phosphate product, decreasing pericardial deposition.

Complications

If left untreated, uraemia‑associated pericarditis can lead to serious outcomes:

• Cardiac tamponade: Rapid accumulation of fluid compresses the heart, causing hypotension, shock, and death if not drained emergently.
• Constrictive pericarditis: Chronic inflammation may thicken and scar the pericardium, leading to fixed diastolic dysfunction.
• Arrhythmias: Electrolyte shifts and pericardial irritation increase risk of atrial fibrillation or ventricular tachycardia.
• Worsening renal insufficiency: Ongoing uremia perpetuates a cycle of toxin accumulation.
• Reduced quality of life: Chronic chest pain and dyspnea limit activity and can cause depression.

When to Seek Emergency Care

---

References:
[1] Kimmel PL. “Pericarditis in the renal failure patient.” Cleveland Clinic Journal of Medicine. 2020;87(12):861‑867.
[2] National Kidney Foundation. “Uremic Pericarditis.” Kidney Disease: Improving Global Outcomes (KDIGO) Guidelines, 2023.
[3] Mayo Clinic. “Pericarditis.” Updated 2022.
[4] CDC. “Chronic Kidney Disease in the United States.” 2022.
[5] NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Living With Kidney Failure.” 2021.

```